Latest Breaking News On - Central cancer registries - Page 12 : comparemela.com

SHARE ASCO GU 2021: Association of Reductions in PSA Screening Across States with Increased Metastatic Prostate Cancer in the United States Published 13 February 2021 (UroToday.com) Prostate cancer screening using prostate-specific antigen (PSA) testing has been controversial since shortly after its introduction in large part due to concerns of over-diagnosis and over-treatment, with the associated morbidity. Thus, despite improvements in prostate cancer-related metastasis and mortality demonstrated in the European Randomized Study of Screening for Prostate Cancer (ERSPC) randomized trial from Europe, PSA screening has remained contentious. In both 2008 and 2012, the US Preventive Services Task Force (USPSTF) did not recommend PSA screening. Some have attributed increased rates of metastatic prostate cancer in the US to reductions in PSA screening as a result of these recommendations from the USPSTF. To test this hypothesis, in the Poster Highlights: Prostate Cancer - Localized

United statesVanderbilt universityChristopher jd wallisVidit sharmaUs preventive services task forceVanderbilt university medical centerAmerican society of clinical oncologyAmerican association of central cancer registriesEuropean randomized studyProstate cancerServices task forcePoster highlightsDisease sessionClinical oncologyCancers symposiumNorth american association